Evidence map›Paper›PMID 30125643›Full record

ReviewNeuroscience letters2018

CK2 inhibition protects white matter from ischemic injury.

Selva Baltan, Chinthasagar Bastian, John Quinn, Danielle Aquila, Andrew McCray, Sylvain Brunet

Open access · greenAbstract readReview
In one paragraph

Review in Neuroscience letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Casein Kinase 2 Signaling in White Matter Stroke.Frontiers in molecular biosciences · 2022
    Review
  5. Review
  6. Review
  7. New insights into targeting mitochondria in ischemic injury.Apoptosis : an international journal on programmed cell death · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Selva BaltanDepartment of Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Chinthasagar BastianDepartment of Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
John QuinnDepartment of Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Danielle AquilaDepartment of Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Andrew McCrayDepartment of Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Sylvain BrunetDepartment of Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. Electronic address: brunets@ccf.org.
Cleveland Clinic · US

Funding

Vulnerability of Aging White Matter to IschemiaR01AG033720 · NIA · UNIVERSITY OF WASHINGTON · PI BALTAN, SELVA · 2010 to 2021
$2.7M
Casein kinase 2 signaling in axonal injuryR21NS094881 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI BALTAN, SELVA · 2016 to 2017
$436k
Vulnerability of Aging White Matter to IschemiaR56AG033720 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BALTAN, SELVA · 2016 to 2016
$396k
NIA NIH HHS R01 AG033720NIA NIH HHS R56 AG033720NINDS NIH HHS R21 NS094881
6 · The paper itself

Abstract

Strokes occur predominantly in the elderly and white matter (WM) is injured in most strokes, contributing to the disability associated with clinical deficits. Casein kinase 2 (CK2) is expressed in neuronal cells and was reported to be neuroprotective during cerebral ischemia. Recently, we reported that CK2 is abundantly expressed by glial cells and myelin. However, in contrast to its role in cerebral (gray matter) ischemia, CK2 activation during ischemia mediated WM injury via the CDK5 and AKT/GSK3β signaling pathways (Bastian et al., 2018). Subsequently, CK2 inhibition using the small molecule inhibitor CX-4945 correlated with preservation of oligodendrocytes as well as conservation of axon structure and axonal mitochondria, leading to improved functional recovery. Notably, CK2 inhibition promoted WM function when applied before or after ischemic injury by differentially regulating the CDK5 and AKT/GSK3β pathways. Specifically, blockade of the active conformation of AKT conferred post-ischemic protection to young, aging, and old WM, suggesting a common therapeutic target across age groups. CK2 inhibitors are currently being used in clinical trials for cancer patients; therefore, it is important to consider the potential benefits of CK2 inhibitors during an ischemic attack.

Indexed as

AnimalsBrain IschemiaCasein Kinase IIHumansNaphthyridinesNeuroprotective AgentsPhenazinesWhite MatterCasein Kinase IINaphthyridinesNeuroprotective AgentsPhenazinessilmitasertibAgingCasein kinase 2CK2IschemiaProtein kinaseSignalingStroke

Identifiers

PMID30125643
PMCPMC9084538
OpenAlexW2887143567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.